Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNB8802v1 in Enteric Hyperoxaluria
NCT05377112Phase 1Completed
- Sponsor
- Synlogic
- Start
- Mar 2022
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in enteric hyperoxaluria (EH) comparing SYNB8802v1 with Placebo (2 arms). Primary endpoints: Safety and tolerability of SYNB8802v1, as assessed by measuring of vital signs at 17 days, Safety and tolerability of SYNB8802v1 by assessing clinical laboratory tests at 17 days and 1 more. Started Mar 2022; status: completed.
02
Drugs
synb8802
03
Conditions
enteric hyperoxaluria (EH)
Beyond the preview
Go deeper on NCT05377112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05377112.